Blood Cancer Discovery with Drs. Nikhil C. Munshi, Kenneth C. Anderson, Malin Hultcrantz, and Ola Landgren
Moderated by: Tanya Bondar, PhD, Blood Cancer DiscoveryDeputy Editor
Watch the recording of the AACR Virtual Journal Club: Blood Cancer Discovery session, featuring Nikhil C. Munshi from Dana-Farber Cancer Institute, Kenneth C. Anderson from Dana-Farber Cancer Institute, Malin Hultcrantz from Memorial Sloan Kettering Cancer Center, and Ola Landgren from Sylvester Comprehensive Cancer Center at University of Miami, as they discuss their research relating to COVID-19 and the treatment of multiple myeloma patients in their recently published Blood Cancer Discovery articles:
"Don't Compromise Myeloma Care Due to COVID-19 Pandemic!" Patients with active myeloma, especially with earlier stages of the disease, are susceptible to COVID-19 infection and can have adverse outcomes, even in those on first-line treatment. Importantly, myeloma therapy can be safely administered, and optimal control of myeloma is associated with improved outcome.
And "COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers". Patients with multiple myeloma are immunocompromised, raising the question whether they are at higher risk of severe COVID-19 disease. In this large case series on COVID-19 in patients with multiple myeloma, the research shows a 29% mortality rates among hospitalized patients and identify race/ethnicity as the most significant risk factor for severe outcome.
Stay tuned for the Q&A session at the end of the recording.
About the Featured Speakers:
Nikhil C. Munshi, MD is a Professor of Medicine in the Department of Medicine at Harvard Medical School, Kraft Family Chair at Dana-Farber Cancer Institute as well as an attending physician at VA Boston Healthcare System.
Kenneth C. Anderson, MD is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute.
Malin Hultcrantz, MD, PhD is a board-certified hematologist at Memorial Sloan Kettering Cancer Center who specializes in the treatment of multiple myeloma and related plasma cell disorders.
Ola Landgren, MD, PhD is a professor of medicine and the Chief of the Myeloma Service and the Chair of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami.